1 week Ago By ABMN Staff
Corebridge Financial Inc. increased its stake in Wave Life Sciences Ltd. ( NASDAQ:WVE – Free Report ) by 10.
7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,824 shares of the company’s stock after acquiring an additional 4,423 shares during the quarter. Corebridge Financial Inc.
’s holdings in Wave Life Sciences were worth $567,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds also recently modified their holdings of the stock. KBC Group NV acquired a new position in shares of Wave Life Sciences in the 4th quarter valued at $67,000.
Point72 DIFC Ltd purchased a new stake in Wave Life Sciences during the third quarter valued at about $98,000. Orion Portfolio Solutions LLC acquired a new position in shares of Wave Life Sciences in the third quarter worth about $123,000. XTX Topco Ltd purchased a new position in shares of Wave Life Sciences in the third quarter worth approximately $126,000.
Finally, Raymond James Financial Inc. acquired a new stake in shares of Wave Life Sciences during the fourth quarter valued at approximately $157,000. 89.
73% of the stock is owned by institutional investors and hedge funds. Insider Activity at Wave Life Sciences In other news, Director Christian O. Henry sold 10,500 shares of the stock in a transaction dated Thursday, March 20th.
The stock was sold at an average price of $9.77, for a total transaction of $102,585.00.
Following the transaction, the director now owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. This represents a 39.
45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction that occurred on Friday, March 7th.
The shares were sold at an average price of $9.57, for a total value of $1,617,569.25.
Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.
31 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders own 29.
10% of the company’s stock. Analysts Set New Price Targets Read Our Latest Stock Report on Wave Life Sciences Wave Life Sciences Trading Down 3.8 % WVE opened at $5.
80 on Tuesday. The stock has a fifty day moving average price of $10.17 and a 200 day moving average price of $11.
77. Wave Life Sciences Ltd. has a 1 year low of $4.
25 and a 1 year high of $16.74. The stock has a market cap of $890.
22 million, a price-to-earnings ratio of -5.23 and a beta of -0.93.
Wave Life Sciences ( NASDAQ:WVE – Get Free Report ) last announced its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
17) by $0.34. The business had revenue of $83.
75 million during the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.
57% and a negative net margin of 66.50%. As a group, sell-side analysts forecast that Wave Life Sciences Ltd.
will post -1.14 earnings per share for the current fiscal year. About Wave Life Sciences ( Free Report ) Wave Life Sciences Ltd.
, a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Read More Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd. ( NASDAQ:WVE – Free Report ). Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
